Connection
Philip Zeitler to Linagliptin
This is a "connection" page, showing publications Philip Zeitler has written about Linagliptin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.051 |
|
|
|
-
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023 03; 11(3):169-181.
Score: 0.051